Skip to Content

How does Venclexta work?

Medically reviewed by Last updated on May 20, 2019.

Official Answer


Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), and acute myeloid leukemia (AML).

The BCL-2 protein prevents apoptosis (programmed cell death) of some cells, including lymphocytes, and it can be highly expressed in CLL and AML. Venetoclax is designed to selectively inhibit the function of the BCL-2 protein, leading to the restoration of the signaling system that tells the cancer cells to self-destruct.

Related Medical Questions

Drug Information

Related Support Groups